« Previous
Next »
Titles
- Tale of two states: transforming child care in New Mexico and Alabama1
- Tax administration: IRS oversight of hospitals’ tax-exempt status : testimony before the Subcommittee on Oversight, Committee on Ways and Means, House of Representatives1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1
- Technical considerations for medical devices with physiologic closed-loop control technology: guidance for industry and Food and Drug Administration staff1
- Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry1
- The Food and Drug Administration needs to improve the premarket tobacco application review process for electronic nicotine delivery systems to protect public health1
- The Medicare and Medicaid Improvement Funds: budgetary history and projections1
- The Provider Relief Fund helped select nursing homes maintain services during the COVID-19 pandemic, but some found guidance difficult to use1
- The Strategic National Stockpile was not positioned to respond effectively to the COVID-19 pandemic1
- The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern1
- The demographic outlook: 2023 to 20531
- The foreign-born population, the U.S. economy, and the federal budget1
- The illusion of parent choice: lessons learned from BPC’s parent survey series1
- The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D1
- The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 20221
- The role of telehealth in achieving a high performing rural health system: priorities in a post-pandemic system1
- Toolkit: analyzing telehealth claims to assess program integrity risks1
- Tracking the funds. Specific fiscal year 2023 provisions for the Office of National Drug Control Policy1
- Transition plan for medical devices issued emergency use authorizations (EUAs) related to coronavirus disease 2019 (COVID-19): guidance for industry, other stakeholders, and Food and Drug Administration staff1
- Transition plan for medical devices that fall within enforcement policies issued during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry, other stakeholders, and Food and Drug Administration staff1